The European Medicines Agency's pharmacovigilance committee (PRAC), which is meeting this week, is expected to adopt final recommendations on the anti-epileptic drug, valproate, to address ongoing concerns with its use in women and girls who are pregnant or of childbearing age.
The drug, originally from Sanofi but now widely available as a generic, was the subject of PRAC's first ever public...




